Mobidiag and Autobio form joint venture for Novodiag platform in China

Mobidiag and Autobio Diagnostics formed a joint venture to commercialise the Novodiag platform in China, with a total investment of €12.3 million. Mobidiag holds 35% and Autobio 65%.

“Finnish molecular diagnostics developer Mobidiag has signed an agreement with Chinese clinical diagnostics company Autobio Diagnostics to form a joint venture (JV) firm to commercialise its Novodiag platform in China.”medicaldevice-network.com

• 1 source
• medicaldevice-network.comMobidiag, Autobio form JV to commercialise Novodiag platform in ChinaDivya TirumalarajuDec 18, 2018

Summarized from public sources; check the original articles before acting on it.